This hampers the development of therapies for patients with HER2-positive breast cancer with drug-resistant lung metastases, since preclinical models can be indispensable not only for comparisons of the approved anti-HER2 targeted agents, but for the development of novel agents and novel drug combinations as well. This evidence concerns the gene ERBB2 and breast carcinoma.